Deltex Medical gains ODM investment from NHS hospital
AIM-listed Deltex Medical Group won its most substantial account with an NHS hospital for more than two years as a hospital bought six of the company’s oesophageal doppler monitoring (ODM) products.
Deltex Medical Group
0.08p
12:35 24/12/24
FTSE AIM All-Share
717.40
13:14 24/12/24
Health Care Equipment & Services
10,763.40
12:54 24/12/24
A 450 bed NHS hospital in the southeast of England bought six CardioQ-ODM+ monitors and an initial stock of single patient oesophageal probes for use in its peri-operative surgical care, for over £30,000.
Deltex Medical said the contract win does not alter full-year forecasts, but does reflect a generally improving performance in the second half of the year to date.
The company said the investment in ODM was a response to demand from clinicians to replace the alternative technology the trust bought as a result of the 2013 NHS national implementation programme for Intra-Operative Fluid Management.
Chief executive Ewan Phillips said the company was encouraged that clinicians are insisting on using ODM rather than alternative technologies and that NHS hospitals will support clinicians financially to deliver better outcomes and reduce costs.
He added: “This order is further evidence of improving trends in our UK business following the launch of the TruFlow probes in May, the presentation of excellent results from the largest ever randomised controlled trial of ODM in June and the further presentation in July of a trial from a major NHS hospital confirming better comparative outcomes from using ODM during surgery."
Shares in Deltex Medical Group were up 9.09% to 4.50p at 1006 GMT.